Regulatory - Pharmaceutical Executive

ADVERTISEMENT

Regulatory
New developments and strategies for success in dealing with FDA, OIG, SEC, EMEA, and more.

Costs and Benefits of Health Reform

February 1, 2012

Will expanded markets and ACOs offset higher rebates, added fees, and closer scrutiny of marketing and prices?

Tightening the Compliance Net

February 1, 2012

A dissection of the new Sunshine regulations in the Affordable Care Act

Industry Trees are Falling, But is FDA Around to Hear?

February 1, 2012

Experts weigh in on FDA's long-awaited social media guidelines.

Essential Questions for Essential Benefits

January 1, 2012

A key consideration under the Affordable Care Act is how states select plans for drug coverage.

New Year, New Issues

January 1, 2012

Look for action in 2012 on drug access, shortages, innovation, and transparency.

The Payoff for Payers

December 1, 2011

Thorough risk assessment is essential before placing bets on good evidence that clears a path to approval.

Spotlight on OTCs

November 1, 2011

With OTCs challenging traditional approaches to quality, new opportunities are arising to support industry innovation and advance public health.

The Drug Shortages Struggle

November 1, 2011

Clamor for critical therapies prompts probes of prices, production practices.

Janet Woodcock: At the Helm of Industry

October 1, 2011

Janet Woodcock, MD, Director, FDA Center for Drug Evaluation and Research

ADVERTISEMENT

Click here